TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33222472
Drug: Hypofractionated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated radiation therapy (40 Gy in 15 fractions) concomitantly with temozolomide (TMZ) followed by adjuvant TMZ
Study: 32675772
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg plus Rilpivirine 25 mg (early-switch group)
Study: 32675772
Drug: Dolutegravir 50
Normalized name: dolutegravir 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolutegravir 50 mg plus Rilpivirine 25 mg (late-switch group)
Study: 33693741
Drug: Galacto-Oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-Oligosaccharides (GOS) with iron fortified maize porridge (5 mg iron as FeFum + NaFeEDTA)
Study: 33693741
Drug: Galacto-Oligosaccharides (GOS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galacto-Oligosaccharides (GOS) with iron fortified maize porridge (5 mg iron as FeSO4)
Study: 33693741
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified maize porridge (5 mg iron as FeFum + NaFeEDTA) without GOS
Study: 33693741
Drug: Iron fortified
Normalized name: INFANT FORMULA SMA IRON FORTIFIED PWD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron fortified maize porridge (5 mg iron as FeSO4) without GOS
Study: 34304674
Drug: Mogamulizumab (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mogamulizumab (1.0 mg/kg intravenously weekly)
Study: 34304674
Drug: Vorinostat (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vorinostat (400 mg orally daily)
Study: 35891246
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of CoronaVac® with 14 days between doses
Study: 35891246
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of CoronaVac® with 28 days between doses
Study: 32891160
Drug: Gum Arabic
Normalized name: Gum arabic
DrugBank: Acacia (DB10451)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gum Arabic (GA) 30-grams-dose once daily for four weeks
Study: 32891160
Drug: Placebo (pectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (pectin powder 1-gram-dose once daily for four weeks)
Study: 33952313
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual by the GP
Study: 33619667
Drug: Life-Sustaining Treatment
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-Sustaining Treatment (LST) for severe disability scenario
Study: 33619667
Drug: Life-Sustaining Treatment
Normalized name: Life-O-Gen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Life-Sustaining Treatment (LST) for vegetative state scenario
Study: 32144926
Drug: Head-nine-needle therapy
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-nine-needle therapy
Study: 32144926
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine control (epiperisone hydrochloride and fluoguili hydrochloride)
Study: 33376120
Drug: One-week interval
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-week interval oral health intervention
Study: 33376120
Drug: Two-week interval
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-week interval oral health intervention
Study: 34454817
Drug: Primary stenting,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary stenting, best medical treatment (BMT) and exercise advice (stent group)
Study: 34454817
Drug: Best medical
Normalized name: calcium polycarbophil
DrugBank: Calcium polycarbophil (DB14684)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best medical treatment (BMT) and exercise advice alone (control group)
Study: 33941629
Drug: Nonoperative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonoperative treatment (upper limb immobilisation in long arm cast for 4 weeks)
Study: 34338389
Drug: Increasing buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing buprenorphine-naloxone (BUP-NX) dose in response to opioid use
Study: 34338389
Drug: Constant buprenorphine-naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Constant buprenorphine-naloxone (BUP-NX) dose after week 2
Study: 35614586
Drug: Neuromobilisation along
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromobilisation along with conservative treatment (ultrasound therapy, wrist splinting, tendon-gliding exercises)
Study: 35614586
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (ultrasound therapy, wrist splinting, tendon-gliding exercises)
Study: 32517847
Drug: DBV712 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBV712 250 µg
Study: 35164720
Drug: IPSRT-CR (Interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPSRT-CR (Interpersonal and Social Rhythm Therapy with Cognitive Remediation)
Study: 35164720
Drug: IPSRT (Interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: IPSRT (Interpersonal and Social Rhythm Therapy) alone
Study: 35818122
Drug: Intensive arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive arm (8 phone sessions + 8 weeks of nicotine patches)
Study: 35818122
Drug: Minimal arm
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal arm (3 phone sessions + 2 weeks of nicotine patches)
Study: 32374959
Drug: Endovascular thrombectomy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular thrombectomy preceded by intravenous alteplase (0.9 mg/kg within 4.5 hours after symptom onset)
Study: 32374959
Drug: Combination-therapy group
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination-therapy group (thrombectomy with alteplase)
Study: 35565845
Drug: Beet It
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beet It Sport® plus 200 mg vitamin C
Study: 35565845
Drug: Beet It
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beet It Sport® plus 15 g of whey protein
Study: 35565845
Drug: Beet It
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beet It Sport® (all treatments)
Study: 34687316
Drug: Rituximab (500mg)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab (500mg) with 12 months of antithyroid drug (ATD)
Study: 35002984
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no metformin therapy)
Study: 35439582
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure control (combination of perindopril‐indapamide)
Study: 35701080
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality modulator and silicone suture pads (group B)
Study: 33388987
Drug: Potassium‐competitive acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium‐competitive acid blocker (P‐CAB)
Study: 33388987
Drug: Serotonin noradrenaline
Normalized name: serotonin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serotonin noradrenaline reuptake inhibitor (SNRI)
Study: 32546262
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics plus orally administered DBT for 10 days
Study: 32546262
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics plus placebo for 10 days
Study: 32546262
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics plus orally administered DBT
Study: 32546262
Drug: Intravenous antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous antibiotics plus placebo
Study: 35322978
Drug: Autologous bone
Normalized name: Human autologous bone marrow derived osteoblastic cells
DrugBank: Human autologous bone marrow derived osteoblastic cells (DB18259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous bone marrow MSCs injection
Study: 32399578
Drug: Zinc oxide
Normalized name: Zinc Oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc oxide treatment
Study: 35072641
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioral therapy (6 weekly sessions, with telephone support)
Study: 35144952
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (hospital vaccine availability, ease of access and reminders for WCH subspecialists)
Study: 35463906
Drug: L:R (lactulose:rhamnose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L:R (lactulose:rhamnose)
Study: 35463906
Drug: L:M (lactulose:mannitol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L:M (lactulose:mannitol)
Study: 32729586
Drug: 3 g
Normalized name: Molds 3 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g intragastric tryptophan (Trp)
Study: 35460310
Drug: Angelica gigas
Normalized name: ANGELICA GIGAS ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angelica gigas Nakai root extracts (ARE) lotion
Study: 35897370
Drug: Clonazepam 0.5
Normalized name: clonazepam 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonazepam 0.5 mg for 4 weeks
Study: 34551225
Drug: mRNA‐1273 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA‐1273 vaccine (100 ?g)
Study: 35958596
Drug: sIPV +
Approvals — FDA: no, EMA: no, PMDA: no
Description: sIPV + DTaP concomitant administration
Study: 32003357
Drug: Endoscopic injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic injection sclerotherapy (Group A)
Study: 33501972
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing at visits that met criteria (205/214)
Study: 33501972
Drug: Antibiotic prescribing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic prescribing at visits that did not meet criteria (193/211)
Study: 33834628
Drug: Remibrutinib (0.5‒600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib (0.5‒600 mg)
Study: 33834628
Drug: Remibrutinib (>=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib (>= 10 mg q.d.)
Study: 33834628
Drug: Remibrutinib (>=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib (>= 50 mg q.d.)
Study: 33834628
Drug: Remibrutinib (>=
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remibrutinib (>= 100 mg q.d.)
Study: 32173730
Drug: Intravenous Tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous Tranexamic Acid (TXA) 1-g dose prior to skin incision and another 1-g dose 4 hours later
Study: 34187822
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment for MSF
Study: 34187822
Drug: Non-surgical treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical treatment for MSF
Study: 33497293
Drug: Caffeine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (6 mg · kg−1)
Study: 36123569
Drug: Neuromuscular blockade
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neuromuscular blockade (NMB) agent
Study: 33565308
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mycophenolate mofetil (MMF) with low dose prednisolone
Study: 33565308
Drug: Cyclosporine (CsA)
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine (CsA) with low dose prednisolone
Study: 35179709
Drug: AQCH 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: AQCH 400 mg orally three times a day plus standard of care
Study: 34051293
Drug: Mirtazapine 15mg
Normalized name: MIRTAZAPINE 15MG TAB
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mirtazapine 15mg daily at night for 8 weeks
Study: 34515824
Drug: LSD (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LSD (all doses combined)
Study: 37357904
Drug: Moxidectin (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxidectin (8 mg) and Albendazole (400 mg)
Study: 36354034
Drug: Ivermectin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (200 μg/kg) and Albendazole (400 mg)
Study: 36121246
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery denervation (PADN) plus a phosphodiesterase‐5 inhibitor (PDE‐5i)
Study: 36121246
Drug: Sham procedure
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sham procedure plus a phosphodiesterase‐5 inhibitor (PDE‐5i)
Study: 35045351
Drug: Intravenous trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trehalose (15 g once weekly) for 12 weeks
Study: 35045351
Drug: Intravenous trehalose
Normalized name: Trehalose
DrugBank: Trehalose (DB12310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous trehalose
Study: 33562341
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry juice (240 mL once daily for 90 days)
Study: 33562341
Drug: Montmorency tart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montmorency tart cherry juice (240 mL twice daily for 90 days)
Study: 35499912
Drug: Omega-3 (fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (fish oil; 1440 mg/day of docosahexaenoic acid)
Study: 35474254
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) with oral micronized 17β-estradiol 1 mg/day for hysterectomized women and 4% vaginal micronized progesterone gel 45 mg/day for 10 days each month added to estradiol for women with a uterus.
Study: 32868544
Drug: 1g TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g TXA bolus/1g TXA infusion (Bolus Maintenance [BM])
Study: 32868544
Drug: 2g TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2g TXA bolus/placebo infusion (Bolus Only [BO])
Study: 32868544
Drug: Placebo bolus/placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo bolus/placebo infusion (Placebo)
Study: 32868544
Drug: 1g TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1g TXA bolus/1g TXA infusion (Bolus Maintenance [BM]) and 2g TXA bolus/placebo infusion (Bolus Only)
Study: 35647824
Drug: 0.2% hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% hyaluronic acid gel Gengigel®
Study: 35647824
Drug: 0.01% hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% hyaluronic acid spray Gengigel®
Study: 33530745
Drug: Erythropoietin (20,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (20,000 units) injected subcutaneously the day before, day of, and day after surgery for 3 doses
Study: 32489005
Drug: Self-regulation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-regulation intervention using a weight tracking app and daily/weekly questionnaires
Study: 32489005
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (daily self-weighing without intervention)
Study: 35623048
Drug: 20-day antibiotic
Normalized name: Antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20-day antibiotic therapy
Study: 34098395
Drug: Fibrinogen (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fibrinogen (2 g fibrinogen concentrate diluted in 100 ml distilled water, intravenously 15-30 min before surgery)
Study: 34098395
Drug: Placebo (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (100 ml normal saline, intravenously 15-30 min before surgery)
Study: 32277749
Drug: Gospel music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gospel music program with weekly, 45-minute vocal and instrumental sessions
Study: 35654820
Drug: Oral methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral methotrexate (MTX) and 6-mercaptopurine (6-MP) as maintenance therapy
Study: 32965249
Drug: Allopurinol 300
Normalized name: allopurinol 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 300 mg per day with titration of 100 mg once a month + synbiotic 1 capsule three times a day
Study: 32965249
Drug: Allopurinol monotherapy
Normalized name: Allopurinol
DrugBank: Allopurinol (DB00437)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Allopurinol monotherapy
Study: 34264316
Drug: Nivolumab plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab plus ipilimumab (3 mg/kg every 2 weeks + 1 mg/kg every 6 weeks)
Study: 34264316
Drug: Nivolumab alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab alone (3 mg/kg every 2 weeks)
Study: 33217031
Drug: Lidocaine group
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine group (group L, n = 40) received 1‐mg midazolam, 1.5 mg/kg lidocaine, and 1 mg/kg propofol intravenously
Study: 33217031
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (group C, n = 40) received 1‐mg midazolam, saline in the same volume as the lidocaine group, and 1 mg/kg propofol intravenously
Study: 32628922
Drug: Fluocinolone acetonide
Normalized name: Fluocinolone Acetonide
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluocinolone acetonide implant (0.59 mg)
Study: 32628922
Drug: Systemic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic therapy (corticosteroid plus immunosuppression)
Study: 33913373
Drug: Thiamin 90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiamin 90 mg/day combined with folic acid 30 mg/day
Study: 32555047
Drug: Control (Acetaminophen)
Normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control (Acetaminophen)
Study: 36228734
Drug: Vonoprazan, 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan, 20 mg
Study: 36228734
Drug: Vonoprazan, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vonoprazan, 10 mg
Study: 36228734
Drug: Lansoprazole, 30
Normalized name: Lansoprazole, 30 mg oral tablet, disintegrating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole, 30 mg
Study: 32227638
Drug: Intravenous thrombolysis
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolysis (alteplase)
Study: 33667726
Drug: KHK inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: KHK inhibitor PF‐06835919
Study: 33667726
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of PF‐06835919
Study: 35803627
Drug: Online self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online self-management fall prevention intervention (group-based, six 2-hour weekly sessions, plus a booster session 8 weeks later)
Study: 36056176
Drug: Loss-framing of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loss-framing of information on vaccine effectiveness
Study: 36056176
Drug: Parental uptake
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parental uptake of the COVID-19 vaccine
Study: 34143241
Drug: Concurrent practice
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent practice (INT concurrent)
Study: 32040044
Drug: Monoclonal anti‐Aβ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal anti‐Aβ antibodies (bapineuzumab, solanezumab, gantenerumab, crenezumab, aducanumab)
Study: 35196381
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) telephone-delivered coaching
Study: 32536587
Drug: Dual-cured self-adhesive
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-cured self-adhesive cement after polyacrylic acid treatment (Group II)
Study: 36016763
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg caffeine (CAF)
Study: 36016763
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 150 mg caffeine, 100 mg methylliberine, and 50 mg theacrine (CMT)
Study: 32516839
Drug: COVID-19 convalescent
Normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 convalescent plasma (CCP) therapy, 200-400 ml of plasma collected from donors with antibody titres > 1:160.
Study: 32959583
Drug: Dynamic scalp
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic scalp acupuncture combined with task-oriented mirror therapy (TOMT)
Study: 32959583
Drug: Task-oriented mirror
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Task-oriented mirror therapy (TOMT)
Study: 35209951
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to initiation of renal replacement therapy or death
Study: 35209951
Drug: Daily cumulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily cumulated vasopressor requirement during ICU stay
Study: 35209951
Drug: Need for
Normalized name: diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Need for a combination of vasopressors and inotropic agents or mechanical circulatory support
Study: 32139505
Drug: Golodirsen (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Golodirsen (30 mg/kg)
Study: 33639181
Drug: HPV vaccination
Normalized name: HPV-16 trojan peptide vaccine
DrugBank: HPV-16 trojan peptide vaccine (DB17496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV vaccination (three doses of Cervarix®)
Study: 32651047
Drug: Section 8
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Section 8 rental voucher (treatment group)
Study: 32651047
Drug: Peer drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer drug use (mediator)
Study: 36278480
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (ICBT) combined with attentional bias modification training (ABM)
Study: 36278480
Drug: Internet-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-based cognitive behavioural therapy (ICBT) combined with ABM placebo
Study: 32909439
Drug: Intra-articular hyaluronic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular hyaluronic acid (HA) injections
Study: 35797024
Drug: Saline nasal
Normalized name: Ayr Saline Nasal
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Saline nasal irrigation (SNI) with 400 mg theophylline